Debiopharm International SA

Oct 03, 2017

Arbor Pharmaceuticals, LLC and Debiopharm International SA Announce Commercial Availability of Triptodur(TM), Triptorelin 6-month Formulation, for Treatment of Central Precocious Puberty (CPP)

Jul 25, 2017

Debiopharm International SA Awarded $2.6 Million Grant from CARB-X to Support Development of Debio 1453 to Fight Drug Resistant Gonorrhea

Jun 28, 2017

GenePOC Announces an Exclusive Distribution Agreement with Cardinal Health Covering the US Market

Jun 28, 2017

GenePOC annonce un accord de distribution exclusif avec Cardinal Health pour le marché américain

Jun 20, 2017

Almac Discovery and Debiopharm International SA Announce a Licensing Agreement for the Development of a Novel Wee-1 Inhibitor

Jun 15, 2017

Debiopharm International SA annonce la fin du recrutement pour une étude clinique de phase I/II portant sur l'administration de Debio 1143 dans le traitement du carcinome épidermoïde de la tête et du cou (SCCHN)

Jun 15, 2017

Debiopharm International SA Announces Completion of Enrollment in Phase I/II Clinical Trial with Debio 1143 in SCCHN

Jun 01, 2017

GenePOC Announces FDA Clearance for Revogene(TM) Instrument and its GBS LB Test

Jun 01, 2017

Debiopharm International SA Announces Results from Phase I Dose-Escalation Study of Debio 1347/CH5183284